PDL BioPharma, Inc. (NASDAQ: PDLI) reported Q2 EPS of $0.52, $0.06 better than the analyst estimate of $0.46. Revenue for the quarter came in at $162.8 million versus the consensus estimate of $134.07 million.

For earnings history and earnings-related data on PDL BioPharma, Inc. (PDLI) click here.